Douglas D. Leipold
Genentech
35 Papers
201 Citations
Douglas D. Leipold is an academic researcher from Genentech. The author has contributed to research in topics: Antibody-drug conjugate & In vivo. The author has an hindex of 17, co-authored 31 publications.
Chat about Author
Papers
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath Reddy Junutula,Helga Raab,Suzanna Clark,Sunil Bhakta,Douglas D. Leipold,Sylvia Weir,Yvonne Chen,Michelle Simpson,Siao Ping Tsai,Mark S. Dennis,Yanmei Lu,Y Gloria Meng,Carl Ng,Jihong Yang,Chien C Lee,Eileen T. Duenas,Jeffrey Gorrell,Viswanatham Katta,Amy Kim,Kevin McDorman,Kevin McDorman,Kelly Flagella,Rayna Venook,Sarajane Ross,Susan D. Spencer,Wai Lee Wong,Henry B. Lowman,Richard Vandlen,Mark X. Sliwkowski,Richard H. Scheller,Paul Polakis,William Mallet +31 more
TL;DR: The favorable in vivo properties of the near-homogenous composition of this conjugate suggest that the strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.
1.3K
Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry.
Keyang Xu,Luna Liu,Ola Saad,Jakub Baudys,Jakub Baudys,Lara Williams,Lara Williams,Douglas D. Leipold,Ben Shen,Helga Raab,Jagath Reddy Junutula,Amy Kim,Surinder Kaur +12 more
TL;DR: A novel method with bead-based affinity capture and capillary liquid chromatography-mass spectrometry to allow direct measurement of drug release by quantifying DAR distributions of the ADC in plasma/serum is demonstrated.
195
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
Hans K. Erickson,Gail Lewis Phillips,Douglas D. Leipold,Carmela A. Provenzano,Elaine Mai,Holly A. Johnson,Bert Gunter,Charlene Audette,Manish Gupta,Jan Pinkas,Jay Tibbitts +10 more
TL;DR: Results indicate that, although the ADC linker can have clear impact on the PK and the chemical nature of the catabolites formed, both linkers seem to offer the same payload delivery to the tumor.
189
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow,Pragya Adhikari,Robert A. Blake,Jinhua Chen,Geoffrey Del Rosario,Gauri Deshmukh,Isabel Figueroa,Karen E. Gascoigne,Amrita V. Kamath,Susan Kaufman,Tracy Kleinheinz,Katherine R. Kozak,Brandon Latifi,Douglas D. Leipold,Chun Sing Li,Ruina Li,Melinda M. Mulvihill,Aimee O'Donohue,Rebecca K. Rowntree,Jack Sadowsky,John S. Wai,Xinxin Wang,Cong Wu,Zijin Xu,Hui Yao,Shang-Fan Yu,Donglu Zhang,Richard Zang,Hongyan Zhang,Hao Zhou,Xiaoyu Zhu,Peter S. Dragovich +31 more
TL;DR: Enhancement of a chimeric protein degrader with poor in vivo properties through antibody conjugation thereby expands the utility of directed protein degradation as both a biological tool and a therapeutic possibility.
144
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
Nelson L. Jumbe,Yan Xin,Douglas D. Leipold,Lisa Crocker,Debra L. Dugger,Elaine Mai,Mark X. Sliwkowski,Paul J. Fielder,Jay Tibbitts +8 more
TL;DR: Key findings of the model were that tumor cell growth rate played a significant role in the sensitivity of tumors to T-DM1; anti-tumor activity was schedule independent; and tumor response was linked to the ratio of exposure to a concentration required for tumor stasis.
115